

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)



(10) International Publication Number
WO 2023/072878 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) *A61P 13/12* (2006.01)
A61K 9/28 (2006.01) *A61P 37/06* (2006.01)
A61K 9/50 (2006.01) *A61P 1/00* (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:

PCT/EP2022/079666

(22) International Filing Date:

24 October 2022 (24.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2021/079584

25 October 2021 (25.10.2021) EP


(71) Applicant: **DR. FALK PHARMA GMBH** [DE/DE];
Leinenweberstr. 5, 79108 Freiburg (DE).

(72) Inventors: **WILHELM, Rudolf**; Feuerkirschenweg 2A,
76476 Bischweier (DE). **TEWES, Bernhard**; Reutacker-
ring 23, 79279 Vörstetten (DE). **GREINWALD, Roland**;
Jakob-Otter-Straße 2, 79341 Kenzingen (DE).

(74) Agent: **ARTH, Hans-Lothar**; ABK Patent Attorneys Jas-
minweg 9, 14052 Berlin (DE).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

(54) Title: ORAL FORMULATION OF A PYRIDINONE DERIVATE AND USE THEREOF IN PROPHYLAXIS AND/OR TREAT-
MENT OF INTESTINAL FIBROSIS



(57) Abstract: The present invention relates to an oral formulation adapted for selective delivery of a drug to the small intestine of a mammal comprising or consisting of: a plurality of particles in form of coated granules, coated pellets, coated beads, coated minicapsules, or coated minitablets, each particle containing (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate of formula (I), or an enantiomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof as the drug, a core material, and an enteric coating polymer, wherein each particle is coated with at least one coating layer containing or consisting of the enteric coating polymer; a preparation method of said oral formulation; and a medical use of said oral formulation in prophylaxis or treatment of intestinal fibrosis, in particular, fibrostenotic

[Continued on next page]

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

Crohn's disease.